Matthew D Griffin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6559561/publications.pdf

Version: 2024-02-01

174 papers 12,844 citations

59 h-index 24982 109 g-index

179 all docs

179 docs citations

179 times ranked

15118 citing authors

#	Article	IF	Citations
1	Reference intervals for commonly requested biochemical and haematological parameters in a healthy Irish adult Caucasian population. Irish Journal of Medical Science, 2022, 191, 301-311.	1.5	3
2	Rates of Reversal of Volume Overload in Hospitalized Acute Heart Failure: Association With Long-term Kidney Function. American Journal of Kidney Diseases, 2022, 80, 65-78.	1.9	7
3	Comparison of Single and Repeated Dosing of Anti-Inflammatory Human Umbilical Cord Mesenchymal Stromal Cells in a Mouse Model of Polymicrobial Sepsis. Stem Cell Reviews and Reports, 2022, 18, 1444-1460.	3.8	7
4	The utility of a genetic kidney disease clinic employing a broad range of genomic testing platforms: experience of the Irish Kidney Gene Project. Journal of Nephrology, 2022, 35, 1655-1665.	2.0	14
5	Targeting stromal cell Syndecanâ€2 reduces breast tumour growth, metastasis and limits immune evasion. International Journal of Cancer, 2021, 148, 1245-1259.	5.1	12
6	A multidisciplinary approach to online support for device research translation: regulatory change and clinical engagement. Health Policy and Technology, 2021, 10, 95-103.	2.5	5
7	Progress toward the Clinical Application of Mesenchymal Stromal Cells and Other Disease-Modulating Regenerative Therapies: Examples from the Field of Nephrology. Kidney360, 2021, 2, 542-557.	2.1	12
8	The genetic landscape of polycystic kidney disease in Ireland. European Journal of Human Genetics, 2021, 29, 827-838.	2.8	11
9	Could NAD+ Precursor Supplements Induce a Legacy of Protection against Diabetic Nephropathy?. Journal of the American Society of Nephrology: JASN, 2021, 32, 1270-1273.	6.1	3
10	Multiplex Serum Biomarker Assays Improve Prediction of Renal and Mortality Outcomes in Chronic Kidney Disease. Kidney360, 2021, 2, 1225-1239.	2.1	4
11	Burden of chronic kidney disease and rapid decline in renal function among adults attending a hospital-based diabetes center in Northern Europe. BMJ Open Diabetes Research and Care, 2021, 9, e002125.	2.8	9
12	Fractalkine (CX3CL1) and Its Receptor CX3CR1: A Promising Therapeutic Target in Chronic Kidney Disease?. Frontiers in Immunology, 2021, 12, 664202.	4.8	23
13	The Clinical Application of Urine Soluble CD163 in ANCA-Associated Vasculitis. Journal of the American Society of Nephrology: JASN, 2021, 32, 2920-2932.	6.1	12
14	TGF- \hat{l}^2 1-Licensed Murine MSCs Show Superior Therapeutic Efficacy in Modulating Corneal Allograft Immune Rejection InÂVivo. Molecular Therapy, 2020, 28, 2023-2043.	8.2	38
15	Human Monocyte Subset Distinctions and Function: Insights From Gene Expression Analysis. Frontiers in Immunology, 2020, 11, 1070.	4.8	54
16	The impact of chronic kidney disease on developed countries from a health economics perspective: A systematic scoping review. PLoS ONE, 2020, 15, e0230512.	2.5	96
17	Editorial: Innovative Biologics and Drugs to Target Renal Inflammation. Frontiers in Pharmacology, 2020, 11, 38.	3.5	1
18	Effects of mesenchymal stromal cells on regulatory T cells: Current understanding and clinical relevance. Stem Cells, 2020, 38, 596-605.	3.2	65

#	Article	IF	CITATIONS
19	Mesenchymal stromal cell–based therapies for acute kidney injury: progress in the last decade. Kidney International, 2020, 97, 1130-1140.	5.2	39
20	Inhibition of IRE1 $\hat{1}$ ± RNase activity reduces NLRP3 inflammasome assembly and processing of pro-IL1 $\hat{1}$ 2. Cell Death and Disease, 2019, 10, 622.	6.3	33
21	Bacterial Cholangitis in Autosomal Dominant Polycystic Kidney and Liver Disease. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2019, 3, 149-159.	2.4	4
22	The Complex Role of Interleukin 6 in Regulating T-cell Responses during Acute Glomerulonephritis. Journal of the American Society of Nephrology: JASN, 2019, 30, 1341-1344.	6.1	5
23	Threading the Needle: Individualized Monitoring Guides the Transition From Cytomegalovirus Prophylaxis to Primary Immune Response in a Face Transplant Recipient. Mayo Clinic Proceedings, 2019, 94, 10-12.	3.0	2
24	TNFâ€Î±/ILâ€1βâ€"licensed mesenchymal stromal cells promote corneal allograft survival <i>via</i> myeloid cellâ€mediated induction of Foxp3 ⁺ regulatory T cells in the lung. FASEB Journal, 2019, 33, 9404-9421.	0.5	37
25	Monogenic causes of chronic kidney disease in adults. Kidney International, 2019, 95, 914-928.	5.2	174
26	Senescence marker activin A is increased in human diabetic kidney disease: association with kidney function and potential implications for therapy. BMJ Open Diabetes Research and Care, 2019, 7, e000720.	2.8	36
27	Human mesenchymal stromal cells broadly modulate high glucose-induced inflammatory responses of renal proximal tubular cell monolayers. Stem Cell Research and Therapy, 2019, 10, 329.	5.5	9
28	High-risk Corneal Transplantation: Recent Developments and Future Possibilities. Transplantation, 2019, 103, 2468-2478.	1.0	75
29	Impact of Early Acute Kidney Injury on Management and Outcome in Patients With Acute Respiratory Distress Syndrome: A Secondary Analysis of a Multicenter Observational Study*. Critical Care Medicine, 2019, 47, 1216-1225.	0.9	36
30	Defining reference intervals for a serum growth differentiation factor-15 (GDF-15) assay in a Caucasian population and its potential utility in diabetic kidney disease (DKD). Clinical Chemistry and Laboratory Medicine, 2019, 57, 510-520.	2.3	20
31	Increased Weight Gain During the Long Interdialytic Period Is Associated with Minor Effects on Blood Pressure Control in Clinically Stable In-Centre Haemodialysis Patients. Nephron, 2019, 141, 87-97.	1.8	4
32	Effect of Sodium Glucose Co-Transporter-2 Inhibition on the Aldosterone/Renin Ratio in Type 2 Diabetes Mellitus. Hormone and Metabolic Research, 2019, 51, 91-99.	1.5	4
33	Phenotypic and functional heterogeneity of human intermediate monocytes based on <pre><scp>HLA</scp>â€<scp>DR</scp> expression. Immunology and Cell Biology, 2018, 96, 742-758.</pre>	2.3	14
34	Antiâ€donor antibody induction following intramuscular injections of allogeneic mesenchymal stromal cells. Immunology and Cell Biology, 2018, 96, 536-548.	2.3	5
35	Extracellular vesicles as modulators of wound healing. Advanced Drug Delivery Reviews, 2018, 129, 394-406.	13.7	116
36	Interspecies Incompatibilities Limit the Immunomodulatory Effect of Human Mesenchymal Stromal Cells in the Rat. Stem Cells, 2018, 36, 1210-1215.	3.2	21

#	Article	IF	CITATIONS
37	Chronic kidney disease, health-related quality of life and their associated economic burden among a nationally representative sample of community dwelling adults in England. PLoS ONE, 2018, 13, e0207960.	2.5	45
38	Chronic Kidney Disease Severity Is Associated With Selective Expansion of a Distinctive Intermediate Monocyte Subpopulation. Frontiers in Immunology, 2018, 9, 2845.	4.8	30
39	Third-Party Allogeneic Mesenchymal Stromal Cells Prevent Rejection in a Pre-sensitized High-Risk Model of Corneal Transplantation. Frontiers in Immunology, 2018, 9, 2666.	4.8	39
40	Patient reported health status and all-cause mortality in patients with coronary heart disease. Family Practice, 2018, 35, 172-178.	1.9	3
41	Allogeneic Mesenchymal Stromal Cells (MSCs) are of Comparable Efficacy to Syngeneic MSCs for Therapeutic Revascularization in C57BKSdb/db Mice Despite the Induction of Alloantibody. Cell Transplantation, 2018, 27, 1210-1221.	2.5	10
42	Factors influencing health-related quality of life in patients with Type 1 diabetes. Health and Quality of Life Outcomes, 2018, 16, 27.	2.4	12
43	Urinary nanovesicles captured by lectins or antibodies demonstrate variations in size and surface glycosylation profile. Nanomedicine, 2017, 12, 1217-1229.	3.3	18
44	Influence of Referral to a Combined Diabetology and Nephrology Clinic on Renal Functional Trends and Metabolic Parameters in Adults With Diabetic Kidney Disease. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2017, 1, 150-160.	2.4	10
45	Distinctive Surface Glycosylation Patterns Associated With Mouse and Human CD4+ Regulatory T Cells and Their Suppressive Function. Frontiers in Immunology, 2017, 8, 987.	4.8	34
46	Anti-Donor Immune Responses Elicited by Allogeneic Mesenchymal Stem Cells and Their Extracellular Vesicles: Are We Still Learning?. Frontiers in Immunology, 2017, 8, 1626.	4.8	116
47	Infliximab Selectively Modulates the Circulating Blood Monocyte Repertoire in CrohnÊ⅓s Disease. Inflammatory Bowel Diseases, 2016, 22, 2863-2878.	1.9	8
48	The Promise of Mesenchymal Stem Cell Therapy for Diabetic Kidney Disease. Current Diabetes Reports, 2016, 16, 42.	4.2	45
49	Bad Memory: CD4 T Cell Presensitization Fosters Antibody-Mediated Kidney Transplant Rejection. Journal of the American Society of Nephrology: JASN, 2016, 27, 3231-3233.	6.1	0
50	Development of a flow cytometry-based potency assay for measuring the in vitro immunomodulatory properties of mesenchymal stromal cells. Immunology Letters, 2016, 177, 38-46.	2.5	14
51	Spatial and Temporal Clustering of Anti-Glomerular Basement Membrane Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1392-1399.	4.5	80
52	Macromolecular crowding meets oxygen tension in human mesenchymal stem cell culture - A step closer to physiologically relevant in vitro organogenesis. Scientific Reports, 2016, 6, 30746.	3.3	66
53	Editorial: A stake in the game: ADAM23 contributes to dendritic cell effectiveness in stimulating CD4 + T cell proliferative responses. Journal of Leukocyte Biology, 2016, 100, 838-841.	3.3	1
54	ANCA-associated vasculitis: a comparison of cases presenting to nephrology and rheumatology services. QJM - Monthly Journal of the Association of Physicians, 2016, 109, 803-809.	0.5	6

#	Article	lF	Citations
55	Culture expanded primary chondrocytes have potent immunomodulatory properties and do not induce an allogeneic immune response. Osteoarthritis and Cartilage, 2016, 24, 521-533.	1.3	23
56	Getting to know the extracellular vesicle glycome. Molecular BioSystems, 2016, 12, 1071-1081.	2.9	78
57	Diet and Major Renal Outcomes: A Prospective Cohort Study. The NIH-AARP Diet and Health Study. , 2016, 26, 288-298.		68
58	Inflammation in AKI. Journal of the American Society of Nephrology: JASN, 2016, 27, 371-379.	6.1	409
59	Mesenchymal Stem Cell-derived Extracellular Vesicles: Toward Cell-free Therapeutic Applications. Molecular Therapy, 2015, 23, 812-823.	8.2	877
60	The Irish Kidney Gene Project - Prevalence of Family History in Patients with Kidney Disease in Ireland. Nephron, 2015, 130, 293-301.	1.8	51
61	Back from the brink: a mesenchymal stem cell infusion rescues kidney function in acute experimental rhabdomyolysis. Stem Cell Research and Therapy, 2014, 5, 109.	5.5	6
62	Chondrogenic Differentiation Increases Antidonor Immune Response to Allogeneic Mesenchymal Stem Cell Transplantation. Molecular Therapy, 2014, 22, 655-667.	8.2	76
63	Modulating kidney transplant interstitial fibrosis and tubular atrophy: is the RAAS an important target?. Kidney International, 2014, 85, 240-243.	5.2	10
64	Mesenchymal stem cells and a vitamin D receptor agonist additively suppress T helper 17 cells and the related inflammatory response in the kidney. American Journal of Physiology - Renal Physiology, 2014, 307, F1412-F1426.	2.7	14
65	Autologous and allogeneic mesenchymal stem cells in organ transplantation. Current Opinion in Organ Transplantation, 2014, 19, 65-72.	1.6	69
66	Alternatively activated macrophages as therapeutic agents for kidney disease: in vivo stability is a key factor. Kidney International, 2014, 85, 730-733.	5.2	23
67	Changes in immunological profile of allogeneic mesenchymal stem cells after differentiation: should we be concerned?. Stem Cell Research and Therapy, 2014, 5, 99.	5.5	61
68	Mesenchymal Stem Cell Therapy Promotes Corneal Allograft Survival in Rats by Local and Systemic Immunomodulation. American Journal of Transplantation, 2014, 14, 2023-2036.	4.7	42
69	The influence of hypoxia on the differentiation capacities and immunosuppressive properties of clonal mouse mesenchymal stromal cell lines. Immunology and Cell Biology, 2014, 92, 612-623.	2.3	24
70	ILâ€10 mediates the immunoregulatory response in conjugated linoleic acidâ€induced regression of atherosclerosis. FASEB Journal, 2013, 27, 499-510.	0.5	50
71	Oral Paricalcitol Reduces the Prevalence of Posttransplant Hyperparathyroidism: Results of an Open Label Randomized Trial. American Journal of Transplantation, 2013, 13, 1576-1585.	4.7	43
72	Concise review: Adult mesenchymal stromal cell therapy for inflammatory diseases: How well are we joining the dots?. Stem Cells, 2013, 31, 2033-2041.	3.2	124

#	Article	IF	Citations
73	Antiâ€donor immune responses elicited by allogeneic mesenchymal stem cells: what have we learned so far?. Immunology and Cell Biology, 2013, 91, 40-51.	2.3	205
74	Blood Pressure Measurement in Peritoneal Dialysis: Which Method is Best?. Peritoneal Dialysis International, 2013, 33, 544-551.	2.3	14
75	The Renal Lymph Node and Immune Tolerance to Filtered Antigens. Journal of the American Society of Nephrology: JASN, 2013, 24, 519-521.	6.1	9
76	Surface Glycosylation Profiles of Urine Extracellular Vesicles. PLoS ONE, 2013, 8, e74801.	2.5	90
77	Double-edged sword: a p53 regulator mediates both harmful and beneficial effects in experimental acute kidney injury. Kidney International, 2012, 81, 1161-1164.	5.2	5
78	Mononuclear phagocyte depletion strategies in models of acute kidney disease: what are they trying to tell us?. Kidney International, 2012, 82, 835-837.	5.2	12
79	Interleukin-1 accounts for intrarenal Th17 cell activation during ureteral obstruction. Kidney International, 2012, 81, 379-390.	5.2	38
80	Identification and Characterization of Kidney Transplants With Good Glomerular Filtration Rate at 1 Year But Subsequent Progressive Loss of Renal Function. Transplantation, 2012, 94, 931-939.	1.0	32
81	The Renal Mononuclear Phagocytic System. Journal of the American Society of Nephrology: JASN, 2012, 23, 194-203.	6.1	243
82	Genetic mismatch affects the immunosuppressive properties of mesenchymal stem cells in vitro and their ability to influence the course of collagen-induced arthritis. Arthritis Research and Therapy, 2012, 14, R167.	3.5	32
83	Defective neutrophil rolling and transmigration in acute uremia. Kidney International, 2011, 80, 447-450.	5.2	11
84	Abnormal circadian blood pressure pattern 1-year after kidney transplantation is associated with subsequent lower glomerular filtration rate in recipients without rejection. Journal of the American Society of Hypertension, 2011, 5, 39-47.	2.3	22
85	Mesenchymal stem cell inhibition of Tâ€helper 17 cell†differentiation is triggered by cell–cell contact and mediated by prostaglandin E2 via the EP4 receptor. European Journal of Immunology, 2011, 41, 2840-2851.	2.9	193
86	Mesenchymal stem cell effects on T-cell effector pathways. Stem Cell Research and Therapy, 2011, 2, 34.	5.5	377
87	Developing Cell-Specific Antibodies to Endothelial Progenitor Cells Using Avian Immune Phage Display Technology. Journal of Biomolecular Screening, 2011, 16, 744-754.	2.6	10
88	The Outcome of Patients with Nephrogenic Systemic Fibrosis after Successful Kidney Transplantation. American Journal of Transplantation, 2010, 10, 558-562.	4.7	20
89	Ghosal hematodiaphyseal dysplasia: A rare cause of a myelophthisic anemia. Pediatric Blood and Cancer, 2010, 55, 1187-1190.	1.5	16
90	Fibrosis with Inflammation at One Year Predicts Transplant Functional Decline. Journal of the American Society of Nephrology: JASN, 2010, 21, 1987-1997.	6.1	194

#	Article	IF	CITATIONS
91	Immunological Aspects of Allogeneic Mesenchymal Stem Cell Therapies. Human Gene Therapy, 2010, 21, 1641-1655.	2.7	272
92	Abstract 4098: The HMGA1-COX-2 axis: A molecular pathway leading to tumor progression in human pancreatic adenocarcinoma. , 2010 , , .		0
93	Genetically modified mesenchymal stem cells and their clinical potential in acute cardiovascular disease. Discovery Medicine, 2010, 9, 219-23.	0.5	17
94	Posttransplant Lymphoproliferative Disorder Following Pancreas Transplantation. American Journal of Transplantation, 2009, 9, 1894-1902.	4.7	34
95	Acute cellular rejection in a renal allograft immediately following leukocyte engraftment after auto-SCT. Bone Marrow Transplantation, 2009, 43, 345-346.	2.4	7
96	Kidney Transplantation for Primary Focal Segmental Glomerulosclerosis: Outcomes and Response to Therapy for Recurrence. Transplantation, 2009, 87, 1232-1239.	1.0	173
97	Patient Survival and Cardiovascular Risk After Kidney Transplantation: The Challenge of Diabetes. American Journal of Transplantation, 2008, 8, 593-599.	4.7	171
98	Survival of Patients on the Kidney Transplant Wait List: Relationship to Cardiac Troponin T. American Journal of Transplantation, 2008, 8, 2352-2359.	4.7	55
99	Case studies in transplant ethics. Transplantation Reviews, 2008, 22, 178-183.	2.9	7
100	Topics in transplant ethics. Transplantation Reviews, 2008, 22, 151-153.	2.9	0
101	Dendritic cells facilitate accumulation of IL-17T cells in the kidney following acute renal obstruction. Kidney International, 2008, 74, 1294-1309.	5.2	77
102	First responders: understanding monocyte-lineage traffic in the acutely injured kidney. Kidney International, 2008, 74, 1509-1511.	5.2	39
103	Pulmonary Hypertension Is Associated With Reduced Patient Survival After Kidney Transplantation. Transplantation, 2008, 86, 1384-1388.	1.0	114
104	Kidney Transplant Histology After One Year of Continuous Therapy With Sirolimus Compared With Tacrolimus. Transplantation, 2008, 85, 1212-1215.	1.0	26
105	Recurrence of ANCA-associated vasculitis following renal transplantation in the modern era of immunosupression. Kidney International, 2007, 71, 1296-1301.	5.2	100
106	Resident dendritic cells are the predominant TNF-secreting cell in early renal ischemia–reperfusion injury. Kidney International, 2007, 71, 619-628.	5.2	301
107	Deficiency of heme oxygenase-1 impairs renal hemodynamics and exaggerates systemic inflammatory responses to renal ischemia. Kidney International, 2007, 72, 1073-1080.	5.2	107
108	Polyomavirus-associated nephropathy risk in kidney transplants: the influence of recipient age and donor gender. Kidney International, 2007, 71, 1302-1309.	5.2	30

#	Article	IF	CITATIONS
109	Diurnal Blood Pressure Changes One Year after Kidney Transplantation: Relationship to Allograft Function, Histology, and Resistive Index. Journal of the American Society of Nephrology: JASN, 2007, 18, 1607-1615.	6.1	60
110	Molecular Evidence of Injury and Inflammation in Normal and Fibrotic Renal Allografts One Year Posttransplant. Transplantation, 2007, 83, 1466-1476.	1.0	36
111	Comparison of Low Versus High Tacrolimus Levels in Kidney Transplantation: Assessment of Efficacy by Protocol Biopsies. Transplantation, 2007, 83, 411-416.	1.0	81
112	Polyomavirus Polymerase Chain Reaction as a Surrogate Marker of Polyomavirus-Associated Nephropathy. Transplantation, 2007, 84, 340-345.	1.0	124
113	Vitamin D receptor-mediated suppression of RelB in antigen presenting cells: A paradigm for ligand-augmented negative transcriptional regulation. Archives of Biochemistry and Biophysics, 2007, 460, 218-226.	3.0	55
114	Renal Hemodynamic, Inflammatory, and Apoptotic Responses to Lipopolysaccharide in HO-1â ⁻ '/â ⁻ ' Mice. American Journal of Pathology, 2007, 170, 1820-1830.	3.8	67
115	HIV-1 Infection and the Kidney: An Evolving Challenge in HIV Medicine. Mayo Clinic Proceedings, 2007, 82, 1103-1116.	3.0	53
116	Reduction of immunosuppression for transplant-associated skin cancer: thresholds and risks. British Journal of Dermatology, 2007, 157, 1183-1188.	1.5	30
117	Transplant Glomerulopathy: Subclinical Incidence and Association with Alloantibody. American Journal of Transplantation, 2007, 7, 2124-2132.	4.7	315
118	Erythropoietin, Gadolinium, and Nephrogenic Fibrosing Dermopathy. Annals of Internal Medicine, 2007, 146, 230.	3.9	3
119	Elevated blood pressure and cardiac hypertrophy after ablation of thegly96/IEX-1gene. Journal of Applied Physiology, 2006, 100, 707-716.	2.5	24
120	Vitamin D-Resistant Rickets and Type 1 Diabetes in a Child With Compound Heterozygous Mutations of the Vitamin D Receptor (L263R and R391S): Dissociated Responses of the CYP-24 and rel-B Promoters to 1,25-Dihydroxyvitamin D3. Journal of Bone and Mineral Research, 2006, 21, 886-894.	2.8	52
121	Complete Avoidance of Calcineurin Inhibitors in Renal Transplantation: A Randomized Trial Comparing Sirolimus and Tacrolimus. American Journal of Transplantation, 2006, 6, 514-522.	4.7	272
122	Kidney Transplant Function and Histological Clearance of Virus Following Diagnosis of Polyomavirus-Associated Nephropathy (PVAN). American Journal of Transplantation, 2006, 6, 1025-1032.	4.7	130
123	Collapsing and non-collapsing focal segmental glomerulosclerosis in kidney transplants. Nephrology Dialysis Transplantation, 2006, 21, 2607-2614.	0.7	52
124	CD28 Ligation Costimulates Cell Death but Not Maturation of Double-Positive Thymocytes due to Defective ERK MAPK Signaling. Journal of Immunology, 2006, 177, 6098-6107.	0.8	12
125	Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist. Journal of Clinical Investigation, 2006, 116 , 2252 - 2261 .	8.2	61
126	Nephrogenic Fibrosing Dermopathy and High-Dose Erythropoietin Therapy. Annals of Internal Medicine, 2006, 145, 234.	3.9	113

#	Article	IF	CITATIONS
127	Blood Pressure and Renal Function after Kidney Donation from Hypertensive Living Donors. Transplantation, 2005, 79, 1769-1770.	1.0	O
128	New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney International, 2005, 67, 2415-2421.	5.2	337
129	MCP-1 is up-regulated in unstressed and stressed HO-1 knockout mice: Pathophysiologic correlates1. Kidney International, 2005, 68, 611-622.	5. 2	98
130	Antigen presentation by dendritic cells in renal lymph nodes is linked to systemic and local injury to the kidney. Kidney International, 2005, 68, 1096-1108.	5.2	123
131	Kidney Allograft Fibrosis and Atrophy Early After Living Donor Transplantation. American Journal of Transplantation, 2005, 5, 1130-1136.	4.7	118
132	Living Donor Kidney and Autologous Stem Cell Transplantation for Primary Systemic Amyloidosis (AL) with Predominant Renal Involvement. American Journal of Transplantation, 2005, 5, 1660-1670.	4.7	83
133	Predicting Subsequent Decline in Kidney Allograft Function from Early Surveillance Biopsies. American Journal of Transplantation, 2005, 5, 2464-2472.	4.7	279
134	Analysis of Polyomavirus-Infected Renal Transplant Recipients' Urine Specimens. American Journal of Clinical Pathology, 2005, 124, 854-861.	0.7	29
135	Regulation of <i>relB</i> in dendritic cells by means of modulated association of vitamin D receptor and histone deacetylase 3 with the promoter. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 16007-16012.	7.1	83
136	Multiple potential clinical benefits for $1\hat{l}_{\pm}$,25-dihydroxyvitamin D3 analogs in kidney transplant recipients. Journal of Steroid Biochemistry and Molecular Biology, 2005, 97, 213-218.	2.5	10
137	Analysis of Polyomavirus-Infected Renal Transplant Recipient's Urine Specimens. American Journal of Clinical Pathology, 2005, 124, 854-861.	0.7	1
138	Patient and graft outcomes from older living kidney donors are similar to those from younger donors despite lower GFR. Kidney International, 2004, 66, 1654-1661.	5.2	72
139	Histologic Findings of Antibody-Mediated Rejection in ABO Blood-Group-Incompatible Living-Donor Kidney Transplantation. American Journal of Transplantation, 2004, 4, 101-107.	4.7	96
140	Correlation of Quantitative Digital Image Analysis with the Glomerular Filtration Rate in Chronic Allograft Nephropathy. American Journal of Transplantation, 2004, 4, 248-256.	4.7	79
141	Gene expression profiles in dendritic cells conditioned by $1\hat{i}\pm,25$ -dihydroxyvitamin D3 analog. Journal of Steroid Biochemistry and Molecular Biology, 2004, 89-90, 443-448.	2.5	37
142	Decline in native renal function early after bladder-drained pancreas transplantation alone. Transplantation, 2004, 77, 844-849.	1.0	37
143	Blood Pressure and Renal Function after Kidney Donation from Hypertensive Living Donors. Transplantation, 2004, 78, 276-282.	1.0	142
144	Pancreas-after-kidney transplantation: an increasingly attractive alternative to simultaneous pancreas-kidney transplantation. Transplantation, 2004, 77, 838-843.	1.0	36

#	Article	IF	Citations
145	Porcine Antigen Presenting Cells Produce Soluble Adjuvants That Stimulate B cells Within and Across the Species. American Journal of Transplantation, 2003, 3, 403-415.	4.7	7
146	Overcoming a Positive Crossmatch in Livingâ€Donor Kidney Transplantation. American Journal of Transplantation, 2003, 3, 1017-1023.	4.7	239
147	Effects of 1α,25(OH)2D3and its analogs on dendritic cell function. Journal of Cellular Biochemistry, 2003, 88, 323-326.	2.6	52
148	Influence of surveillance renal allograft biopsy on diagnosis and prognosis of polyomavirus-associated nephropathy. Kidney International, 2003, 64, 665-673.	5.2	157
149	Generation of antigen-specific, interleukin-10-producing T-cells using dendritic cell stimulation and steroid hormone conditioning. Transplant Immunology, 2003, 11, 323-333.	1.2	43
150	V <scp>ITAMIN</scp> D <scp>AND ITS</scp> A <scp>NALOGS AS</scp> R <scp>EGULATORS OF</scp> I <scp>MMUNE</scp> A <scp>CTIVATION AND</scp> A <scp>NTIGEN</scp> P <scp>RESENTATION</scp> . Annual Review of Nutrition, 2003, 23, 117-145.	10.1	239
151	PKHDL1, a homolog of the autosomal recessive polycystic kidney disease gene, encodes a receptor with inducible T lymphocyte expression. Human Molecular Genetics, 2003, 12, 685-698.	2.9	54
152	Blood Pressure Evaluation among Older Living Kidney Donors. Journal of the American Society of Nephrology: JASN, 2003, 14, 2159-2167.	6.1	57
153	Direct Transcriptional Regulation of RelB by 1α,25-Dihydroxyvitamin D3 and Its Analogs. Journal of Biological Chemistry, 2003, 278, 49378-49385.	3.4	109
154	ABO-incompatible kidney transplantation using both A2 and non-A2 living donors. Transplantation, 2003, 75, 971-977.	1.0	187
155	Synergistic effects of CTLA-4lg and sirolimus on orthotopic lung-allograft survival and histology. Transplantation, 2003, 76, 489-495.	1.0	5
156	PANCREAS-AFTER-KIDNEY (PAK) TRANSPLANTATION: AN INCREASINGLY VIABLE ALTERNATIVE TO SIMULTANEOUS KIDNEY-PANCREAS TRANSPLANTATION (SPK). Transplantation, 2003, 76, S62.	1.0	0
157	Subclinical Rejection in Tacrolimus-Treated Renal Transplant Recipients. Transplantation, 2002, 73, 1965-1967.	1.0	101
158	Distinctive dendritic cell modulation by vitamin D3 and glucocorticoid pathways. Biochemical and Biophysical Research Communications, 2002, 297, 645-652.	2.1	124
159	Can a Transplanted Living Donor Kidney Function Equivalently to its Native Partner?. American Journal of Transplantation, 2002, 2, 252-259.	4.7	33
160	Manipulating the co-stimulatory properties of antigen presenting cells: A key strategy for the promotion of immunologic tolerance. American Journal of Kidney Diseases, 2001, 37, A17.	1.9	0
161	Development and applications of surface-linked single chain antibodies against T-cell antigens. Journal of Immunological Methods, 2001, 248, 77-90.	1.4	25
162	Dendritic cell modulation by $1\hat{A}$,25 dihydroxyvitamin D3 and its analogs: A vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 6800-6805.	7.1	542

#	Article	IF	Citations
163	THE EFFECTS OF CTLA-4Ig ON ACUTE LUNG ALLOGRAFT REJECTION: A COMPARISON OF INTRABRONCHIAL GENE THERAPY WITH SYSTEMIC ADMINISTRATION OF PROTEIN1. Transplantation, 2001, 71, 1867-1871.	1.0	10
164	THYMOGLOBULIN INDUCTION DECREASES REJECTION IN SOLITARY PANCREAS TRANSPLANTATION. Transplantation, 2001, 72, 1671-1675.	1.0	23
165	EFFECT OF CYCLOSPORINE ON GLOMERULAR FILTRATION RATE, SERUM CREATININE, AND REJECTION IN HAPLOIDENTICAL KIDNEY RECIPIENTS Transplantation, 2000, 69, S328.	1.0	0
166	Blockade of T Cell Activation Using a Surface-Linked Single-Chain Antibody to CTLA-4 (CD152). Journal of Immunology, 2000, 164, 4433-4442.	0.8	69
167	Potent Inhibition of Dendritic Cell Differentiation and Maturation by Vitamin D Analogs. Biochemical and Biophysical Research Communications, 2000, 270, 701-708.	2.1	252
168	Molecular Basis of T Cell Inactivation by CTLA-4. Science, 1998, 282, 2263-2266.	12.6	618
169	Neonatal presentation of autosomal dominant polycystic kidney disease with a maternal history of tuberous sclerosis. Nephrology Dialysis Transplantation, 1997, 12, 2284-2288.	0.7	6
170	Cystic kidney diseases. Current Opinion in Nephrology and Hypertension, 1997, 6, 276-283.	2.0	6
171	Expression of polycystin in mouse metanephros and extra-metanephric tissues. Kidney International, 1997, 52, 1196-1205.	5.2	33
172	ClarifyingÂOptimalÂSodium InTakeÂInÂCardiovasular andÂKidney (COSTICK) Diseases: a study protocol for twoÂrandomised controlled trials. HRB Open Research, 0, 4, 14.	0.6	1
173	ClarifyingÂOptimalÂSodium InTakeÂInÂCardiovasular andÂKidney (COSTICK) Diseases: a study protocol for twoÂrandomised controlled trials. HRB Open Research, 0, 4, 14.	0.6	0
174	Peripheral blood immune cell profiling of acute corneal transplant rejection. American Journal of Transplantation, 0, , .	4.7	1